EZZ Life Science Holdings (ASX:EZZ) has entered a manufacturing agreement with US-based GLSP, to produce nutritional supplements for the North American market, according to a Tuesday filing with the Australian bourse.
GLSP will manufacture EZZ-branded products in compliance with the US Food and Drug Administration regulations and under ISO standards, with third-party testing for microbiological and heavy metals safety, the filing added.
The agreement stipulates a production timeline of six to 10 weeks, starting from the receipt of all production requirements and the initial payment, while EZZ will retain full intellectual property rights, including patents and formulations.
Shares of the company fell 6% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.